Peptide Briefs

  • “GLP” Field Guide Part 2: The Approved “GLP”-Class Drugs, Graded

    “GLP” Field Guide Part 2: The Approved “GLP”-Class Drugs, Graded

    Six A’s, two you can’t buy, one that isn’t a peptide. What the grade tells you, and what it doesn’t.

    Peptide Briefs · · Troy Snyder, Ed.D., MBA

    The field guide covered the pipeline. This is the other half of the map: the GLP-class drugs that have already been through a regulator, plus the one combination sitting on the FDA’s desk right now. Seven compounds, each graded the same way the rest of the library is graded. A means peer-reviewed pivotal trials plus a completed regulatory safety review; B means peer-reviewed phase 3 or strong phase 2 without a regulator’s sign-off.

    Six of the seven are A’s, and that is the point of writing them up. An A is not a recommendation and it is not a claim that the drug is the best in its class. Exenatide is an A and has been pulled from the US market. Lixisenatide is an A and was discontinued because nobody wanted it. The grade says the evidence is complete and reviewed. What you do with that is a different question.

    Each section below is short on purpose. These are the best-documented drugs in the entire library, and the full trial records run to hundreds of papers each. I’ve pulled the pivotal trial, the cardiovascular outcomes trial where one exists, the approval history, and the caveat that matters most. Full compound pages will follow for the ones people actually search for.

    Semaglutide

    Evidence grade: A · Also known as Ozempic, Wegovy, Rybelsus; GLP-1 S on some vendor menus.

    What it is. A once-weekly GLP-1 receptor agonist, 31 amino acids, with a C18 fatty diacid on lysine 26 that binds albumin and gives it a half-life of about a week. The oral form uses an absorption enhancer (SNAC) and a much higher dose to get across the stomach wall.

    Why it’s an A. The STEP program (STEP 1, NEJM 2021: 14.9% weight loss at 68 weeks versus 2.4% placebo in 1,961 adults) and the SUSTAIN program for diabetes are peer-reviewed. SELECT (NEJM 2023; 17,604 adults with cardiovascular disease and no diabetes) showed a 20% reduction in major adverse cardiovascular events, the first time an obesity drug did that. FLOW (NEJM 2024) showed kidney protection in type 2 diabetes. The FDA has reviewed all of it: Ozempic for diabetes (December 2017), Rybelsus oral for diabetes (September 2019), Wegovy for obesity (June 2021), cardiovascular risk reduction (March 2024), MASH (August 2025), and the oral Wegovy 25 mg pill (December 22, 2025, based on OASIS 4: 16.6% at 64 weeks).

    Caveat. The gastrointestinal burden is real (74% of STEP 1 participants versus 48% on placebo) and weight returns when treatment stops: the STEP 1 extension showed two-thirds of lost weight regained within a year off drug. Loss of lean mass is a live research question. Semaglutide is also the most counterfeited drug in this class; the FDA stated in June 2026 that sales of unapproved semaglutide products to consumers are illegal, and research-use-only labeling does not change that.

    Key references. Wilding JPH et al., STEP 1, N Engl J Med 2021;384:989 (PMID 33567185). Lincoff AM et al., SELECT, N Engl J Med 2023;389:2221 (PMID 37952131). Marso SP et al., SUSTAIN-6, N Engl J Med 2016;375:1834 (PMID 27633186). Wharton S et al., OASIS 4, N Engl J Med 2025 (PMID 40934115).

    Tirzepatide

    Already has its own page: Tirzepatide (A). Listed here for completeness of the baseline.

    Liraglutide

    Evidence grade: A · Also known as Victoza, Saxenda; generic liraglutide.

    What it is. A once-daily GLP-1 receptor agonist with a C16 fatty acid on lysine 26, half-life about 13 hours. The direct ancestor of semaglutide: same strategy, shorter tail.

    Why it’s an A. SCALE Obesity and Prediabetes (NEJM 2015; 3,731 adults) showed 8.0% weight loss at 56 weeks on 3.0 mg versus 2.6% placebo. LEADER (NEJM 2016; 9,340 adults with type 2 diabetes) showed a 13% reduction in major cardiovascular events and a 22% reduction in cardiovascular death, which made liraglutide the first GLP-1 with a cardiovascular indication (2017). FDA approvals: Victoza for diabetes (January 2010), Saxenda for obesity (December 2014), pediatric diabetes (2019), pediatric obesity (2020). Generic Victoza was approved in December 2024 (Teva, Hikma) and generic Saxenda in August 2025 (Teva), the first generic GLP-1 for weight management.

    Caveat. Daily injection, and the weight loss is roughly half of semaglutide’s in head-to-head data (STEP 8: 15.8% versus 6.4%). A 2024 analysis flagged bone-density declines in Saxenda-treated patients. It matters now mostly because it is the cheapest approved GLP-1 in the US and the one most likely to be substituted for an off-label or compounded product.

    Key references. Pi-Sunyer X et al., SCALE, N Engl J Med 2015;373:11 (PMID 26132939). Marso SP et al., LEADER, N Engl J Med 2016;375:311 (PMID 27295427). Rubino DM et al., STEP 8, JAMA 2022;327:138.

    Dulaglutide

    Evidence grade: A · Also known as Trulicity.

    What it is. Two GLP-1 analogue chains fused to a modified human IgG4 Fc fragment, which is why it is dosed weekly and why it is technically a fusion protein rather than a lipidated peptide.

    Why it’s an A. The AWARD program established glycemic efficacy; FDA approval for type 2 diabetes came in September 2014. REWIND (Lancet 2019; 9,901 adults, median 5.4 years, the longest GLP-1 outcomes trial) showed a 12% reduction in major cardiovascular events in a population that was mostly primary prevention, which earned a cardiovascular indication in February 2020 covering both people with and without established heart disease. Weight loss is modest: about 1.5 kg in REWIND, 4 to 5 kg at the higher 3.0 and 4.5 mg doses in AWARD-11.

    Caveat. It is a diabetes drug, not an obesity drug, and has never been submitted for weight management. Anyone marketing it as a weight-loss peptide is working from the wrong trial record. Not available as a generic.

    Key references. Gerstein HC et al., REWIND, Lancet 2019;394:121 (PMID 31189511). Frias JP et al., AWARD-11, Diabetes Care 2021;44:765.

    Exenatide

    Evidence grade: A · Also known as Byetta, Bydureon, Bydureon BCise; exendin-4.

    What it is. The original. A 39-amino-acid peptide first isolated from Gila monster venom, about 53% identical to human GLP-1 and resistant to DPP-4 breakdown, with a half-life of about 2.4 hours. Byetta was twice-daily; Bydureon wrapped it in microspheres for weekly dosing.

    Why it’s an A. FDA approval in April 2005 made it the first GLP-1 receptor agonist on the market. The AMIGO trials established glycemic control; Bydureon (weekly) followed in 2012. EXSCEL (NEJM 2017; 14,752 adults) showed cardiovascular safety (non-inferiority) but not benefit, with a hazard ratio of 0.91 that just missed significance.

    Caveat. This is an A for a drug you can barely buy. AstraZeneca discontinued Byetta and Bydureon BCise in the US in October 2024 as a business decision; Amneal’s generic exenatide (Byetta equivalent) was approved in November 2024 and is the only form still sold. Weight loss was never the point: 2 to 3 kg in the diabetes trials. It belongs in the library because the entire class descends from it and because it still turns up on research vendor menus at prices that make no sense for a drug with an approved generic.

    Key references. Holman RR et al., EXSCEL, N Engl J Med 2017;377:1228 (PMID 28910237). DeFronzo RA et al., AMIGO, Diabetes Care 2005;28:1092.

    Lixisenatide

    Evidence grade: A · Also known as Adlyxin (US), Lyxumia (EU); the lixisenatide half of Soliqua.

    What it is. A once-daily exendin-4 derivative with a C-terminal polylysine tail, 44 amino acids, short-acting. Its distinguishing feature was a strong effect on post-meal glucose through gastric emptying, with less effect on fasting glucose.

    Why it’s an A. GetGoal program for glycemic control; FDA approval July 2016. ELIXA (NEJM 2015; 6,068 adults after an acute coronary event) showed cardiovascular safety but no benefit, hazard ratio 1.02.

    Caveat. Sanofi discontinued standalone Adlyxin in the US effective January 1, 2023, citing competition and poor sales; it survives only inside Soliqua (with insulin glargine). Weight effect was minimal, around 1 kg. Grade A, commercially dead. If a vendor is listing it, ask what possible research question it answers that liraglutide does not.

    Key references. Pfeffer MA et al., ELIXA, N Engl J Med 2015;373:2247 (PMID 26630143).

    Orforglipron

    Evidence grade: A · Also known as Foundayo. Not a peptide.

    What it is. A once-daily oral small molecule that activates the GLP-1 receptor. Discovered by Chugai, licensed to Lilly in 2018. Because it is not a peptide it has no absorption problem, no food or water restrictions, and cannot be made by peptide synthesis; it belongs in this library only because readers will see it next to the peptides everywhere else.

    Why it’s an A. ATTAIN-1 (NEJM 2025; 3,127 adults without diabetes, 72 weeks) showed 12.4% weight loss at the top dose if everyone adhered, 11.1% on the treatment-regimen estimand, versus 2.1% placebo. ATTAIN-2 covered type 2 diabetes. The FDA approved it for chronic weight management on April 1, 2026, 50 days after filing under the national priority voucher program; diabetes is a separate pending submission. UK authorization followed in 2026.

    Caveat. It loses to every injectable on the scale: roughly half of tirzepatide’s effect and below oral Wegovy’s 16.6%. Nausea ran 29 to 36% versus 10% on placebo, and the approved dose ladder (0.8 to 17.2 mg) differs from the trial’s titration without a published explanation. No cardiovascular outcomes data yet. Boxed thyroid warning like the rest of the class.

    Key references. Wharton S et al., ATTAIN-1, N Engl J Med 2025;393:1796 (doi 10.1056/NEJMoa2511774). FDA approval announcement, April 1, 2026.

    CagriSema

    Evidence grade: B · Cagrilintide 2.4 mg plus semaglutide 2.4 mg, once weekly, one pen.

    What it is. A fixed-dose combination of an amylin analogue and a GLP-1 analogue, two separate peptides co-formulated. Each half has its own page or will shortly: cagrilintide (B) is live; semaglutide is above.

    Why it’s a B and not an A. The pivotal trials are peer-reviewed: REDEFINE 1 (NEJM 2025; n = 3,417) showed 20.4% weight loss at 68 weeks, 22.7% if everyone adhered, versus 3.0% placebo; REDEFINE 2 (NEJM 2025; type 2 diabetes) showed 13.7%. But no regulator has finished a review. Novo Nordisk filed with the FDA on December 18, 2025 and has guided to a decision in the fourth quarter of 2026. REDEFINE 4, the open-label head-to-head against tirzepatide 15 mg, missed its non-inferiority endpoint in February 2026 (20.2% versus 23.6% at 84 weeks). The cardiovascular outcomes trial (REDEFINE 3) is ongoing.

    Caveat. Four in five participants had gastrointestinal side effects. Only 57% of the REDEFINE 1 CagriSema group reached the top dose under a flexible protocol, which the sponsor cites as context for the tirzepatide miss and critics read the other way. A higher-dose version (2.4/7.2 mg) starts phase 3 in the second half of 2026. This grade changes the day the FDA rules; watch Grade Changes.

    Key references. Garvey WT et al., REDEFINE 1, N Engl J Med 2025 (doi 10.1056/NEJMoa2502081). Davies MJ et al., REDEFINE 2, N Engl J Med 2025 (doi 10.1056/NEJMoa2502082). Novo Nordisk, REDEFINE 4 announcement, February 23, 2026.

    What the baseline tells you

    Three things stand out when the approved drugs are lined up this way.

    First, the A grade is about evidence, not usefulness. Two of the six A’s are discontinued, one was never a weight-loss drug, and one isn’t a peptide. If you are reading this library to decide which compound is interesting, the grade is the floor, not the answer.

    Second, the cardiovascular outcomes trials are the real dividing line inside the A’s. Liraglutide, semaglutide and dulaglutide showed benefit. Exenatide and lixisenatide showed safety only. That difference, more than the weight numbers, is why the first three dominate prescribing.

    Third, every pipeline compound in the field guide is measured against this table. UBT251’s 19.7% at 24 weeks is impressive because tirzepatide’s 72-week number is about 21%. Survodutide’s 13% is underwhelming because semaglutide’s is 15%. The baseline is what makes the pipeline numbers mean anything.

    Peptide Briefs is an independent reference and does not sell anything. Its owners co-own a research-peptide vendor; that is disclosed on every page. Nothing here is medical advice or a dosing recommendation.

  • A Field Guide to the “GLP”-Class Pipeline

    A Field Guide to the “GLP”-Class Pipeline

    Twenty molecules are in late-stage development. You’ve heard of four. Here’s what the rest actually show.

    Updated Nov 6, 2026: added CT-G32 (Celltrion), a preclinical four-target candidate.

    Peptide Briefs · · Troy Snyder, Ed.D., MBA

    If you follow this space on X, you could be forgiven for thinking there are four GLP-class molecules in the world: semaglutide, tirzepatide, retatrutide, and whatever a vendor is calling retatrutide this week. There are closer to twenty in late-stage development, several are already approved somewhere, and a few of them are starting to show up on research vendor menus under names most buyers have never seen in a paper.

    This is a field guide to the ones that don’t get talked about. For each I’ll tell you what it is, who makes it, what the human evidence actually shows, and how far it is from a regulator’s desk. I grade the same way the compound pages do: A needs peer-reviewed pivotal data plus a completed regulatory safety review; B is peer-reviewed phase 3 or strong phase 2 without a regulator’s sign-off; C is phase 2 or less; D is preclinical or sponsor press releases only. Where a drug is approved in China but not reviewed by the FDA or EMA, I say so, because a Chinese approval is a real regulatory review and also not the same thing as a US one.

    One framing note before the list. “GLP-1” has become shorthand for a whole family of gut-hormone drugs. Several of the molecules below don’t touch the GLP-1 receptor at all. They are here because they are being developed to do the same job and because they get lumped together on vendor sites.

    The Baseline: What’s Already Approved

    DrugReceptorsStatusGrade
    ExenatideGLP-1FDA 2005; largely discontinuedA
    LiraglutideGLP-1FDA 2010 (T2D), 2014 (obesity); generics 2024A
    LixisenatideGLP-1FDA 2016; discontinued in US 2023A
    DulaglutideGLP-1FDA 2014A
    SemaglutideGLP-1FDA 2017 (T2D), 2021 (obesity), 2024 (CV risk)A
    TirzepatideGLP-1/GIPFDA 2022 (T2D), 2023 (obesity)A
    OrforglipronGLP-1 (small molecule, not a peptide)FDA April 2026A
    CagriSemaGLP-1 + amylin (two peptides, one pen)FDA filed Dec 2025, decision expected Q4 2026B
    RetatrutideGLP-1/GIP/glucagonPhase 3 complete, filing planned early 2027B

    The Chinese Pipeline

    China is now the second center of gravity for this drug class, and two of its molecules are approved there. If you have seen a “Chinese retatrutide” referenced online, it is almost certainly one of the first two below.

    UBT251 — the triple agonist Novo bought

    What it is: A once-weekly synthetic peptide that activates GLP-1, GIP and glucagon receptors, the same three targets as retatrutide. Developed by United Bio-Technology (Hengqin), a subsidiary of The United Laboratories (TUL), Zhuhai. In March 2025 Novo Nordisk licensed worldwide rights outside Greater China for $200 million upfront.

    Evidence: Two Chinese phase 2 trials, both reported by press release in 2026 and not yet peer-reviewed. In adults with overweight or obesity (baseline 92 kg, BMI 33), the 6 mg dose produced a mean weight loss of 19.7% at 24 weeks versus 2.0% on placebo. In type 2 diabetes (211 participants), HbA1c fell up to 2.16% versus 1.77% on semaglutide 1 mg, with weight loss up to 9.8% versus 4.8%. Novo is running a global phase 1b/2a in about 330 people, reading out in 2027, and TUL plans two Chinese phase 3s.

    Why people call it “the Chinese retatrutide”: Same mechanism, similar early numbers (retatrutide’s phase 2 showed 24% at 48 weeks; 19.7% at 24 weeks is on a comparable trajectory), and it is Novo’s answer to Lilly’s molecule. On half-life, I can find no published pharmacokinetic data for UBT251 that would support a claim that it lasts longer than retatrutide. Both are dosed weekly. If a vendor is telling you otherwise, ask them for the paper.

    Grade: C. Phase 2, press-release only, no peer review, no regulator.

    Mazdutide — approved in China, dual GLP-1/glucagon

    What it is: A once-weekly GLP-1 and glucagon receptor dual agonist, originally Lilly’s LY3305677, licensed to Innovent Biologics for China. Brand name Xinermei.

    Evidence: The GLORY-2 phase 3 in Chinese adults with obesity reported 16.7% mean weight loss at 9 mg over 60 weeks; the earlier GLORY-1 phase 3 was published in NEJM in 2024 and the program has since appeared in JAMA and Lancet Diabetes & Endocrinology. A US phase 2 reported up to 18.1% at 16 mg over 32 weeks.

    Regulatory: Approved by China’s NMPA for chronic weight management on June 27, 2025 and for type 2 diabetes on September 19, 2025. No FDA or EMA filing.

    Grade: B. Peer-reviewed phase 3 and a completed regulatory review, but not by the FDA or EMA. If you want to call this an A for China, I won’t argue hard. For a US reader it is a B.

    Ecnoglutide — the “biased” GLP-1

    What it is: A long-acting GLP-1 receptor agonist from Sciwind Biosciences (Hangzhou), engineered to preferentially signal through the cAMP pathway rather than β-arrestin, which in theory means less receptor desensitization. Brand names Xianyida (diabetes) and Xianweiying (weight). Pfizer holds China commercialization rights.

    Evidence: Phase 3 in China reported about 15.1% placebo-adjusted weight loss. The biased-agonism claim is mechanistically interesting and clinically unproven; nobody has shown in humans that it translates to better durability or tolerability than semaglutide.

    Regulatory: NMPA approved for type 2 diabetes (January 30, 2026) and for weight management (March 6, 2026). No US filing announced.

    Grade: B, same logic as mazdutide.

    Bofanglutide (GZR18) — the every-two-weeks GLP-1

    What it is: A long-acting GLP-1 receptor agonist from Gan & Lee Pharmaceuticals (Beijing), dosed once every two weeks. This is the one Chinese molecule where “longer half-life” is actually the selling point.

    Evidence: Phase 3 in China with an extension ongoing; Gan & Lee has signed licensing deals with JW Pharmaceutical (Korea, $81 million, April 2026) and Lupin (India). Published data are thinner than for mazdutide or ecnoglutide.

    Grade: C. It is a single GLP-1 agonist, not a triple, so anyone describing it as a longer-acting retatrutide is wrong on mechanism.

    HRS9531 — Hengrui’s dual agonist

    What it is: A GLP-1/GIP dual agonist (tirzepatide’s mechanism) from Jiangsu Hengrui, in phase 3 in China. Kailera Therapeutics licensed it for the rest of the world in 2024.

    Grade: C pending phase 3 publication.

    The Western pipeline you’ve probably skipped

    Survodutide — the one that read out and underwhelmed

    What it is: Boehringer Ingelheim and Zealand Pharma’s once-weekly GLP-1/glucagon dual agonist (BI 456906).

    Evidence: SYNCHRONIZE-1 (NEJM, June 2026; 76 weeks, 1,481 people without diabetes) reported 12.2% and 13.0% at 3.6 and 6.0 mg versus 5.4% placebo on the primary estimand, or up to 16.6% if everyone adhered. SYNCHRONIZE-2 (NEJM, October 2026, type 2 diabetes) reported 8.2% and 9.8% versus 3.9%. A pre-specified substudy showed 63% liver fat reduction and 34% visceral fat reduction, and the earlier phase 2b in MASH showed histological improvement in up to 83% of patients. The cardiovascular outcomes trial completed in June 2026 with results expected before year end.

    The honest read: This is semaglutide-range weight loss with a potentially better liver story. It is not a tirzepatide competitor on the scale.

    Grade: B. Peer-reviewed phase 3, no regulatory review yet.

    MariTide (maridebart cafraglutide) — the monthly one

    What it is: Amgen’s AMG 133, a GLP-1 receptor agonist peptide fused to an antibody that blocks the GIP receptor. Yes, blocks. Tirzepatide activates GIP; MariTide antagonizes it; both lose weight. Nobody has fully explained this. The antibody scaffold gives it a half-life around three weeks, so it is dosed monthly, and Amgen is testing every-eight-weeks maintenance.

    Evidence: Phase 2 (NEJM 2025) showed up to about 20% weight loss at 52 weeks in people without diabetes and about 17% with type 2 diabetes, with the striking feature that weight stayed off for months after the last dose. Phase 3 (MARITIME-1 and -2) is ongoing with an estimated primary completion in January 2027; as of October 2026 no phase 3 results have been reported. The phase 3 titration was slowed after high rates of nausea and vomiting in phase 2.

    Grade: C, and the most interesting C on this list. If anything here deserves the label “longer half-life than retatrutide,” it is this, and it is a peptide-antibody conjugate, not something a peptide synthesizer can make.

    Amycretin — GLP-1 and amylin in one molecule

    What it is: Novo’s single peptide that activates both the GLP-1 receptor and the amylin receptor, available as a weekly injection and a daily pill. Think CagriSema’s two mechanisms fused into one chain.

    Evidence: Phase 1b/2a injectable showed about 22% weight loss at 36 weeks; the oral form showed about 13% at 12 weeks. Phase 3 began in 2026.

    Grade: C. Early, but this is where Novo is putting its chips after the CagriSema head-to-head miss.

    Eloralintide — Lilly’s amylin-only answer

    What it is: A selective amylin receptor agonist (no calcitonin receptor activity, unlike cagrilintide), weekly injection.

    Evidence: Phase 2 showed up to 20% weight loss at 48 weeks as monotherapy, which is remarkable for an amylin drug on its own. The eloralintide-plus-tirzepatide combination (presented at EASD, September 30, 2026) showed up to 23.3% at 48 weeks in obesity with type 2 diabetes versus 14.8% for tirzepatide 15 mg alone. Phase 3 started late 2025.

    Grade: C, likely B within a year.

    Pemvidutide, VK2735, petrelintide, berobenatide

    Briefly: pemvidutide (Altimmune) is a GLP-1/glucagon dual in phase 2 with a MASH focus; VK2735 (Viking) is a GLP-1/GIP dual in phase 3 with both injectable and oral forms; petrelintide (Zealand, partnered with Roche) is another long-acting amylin analogue in phase 2; berobenatide (Pfizer, formerly Metsera’s MET-097i) is an ultra-long-acting GLP-1 dosed monthly, in phase 3, with 12.3% placebo-adjusted weight loss at 28 weeks in phase 2b. All C or D today.

    The Korea pipeline

    CT-G32 — Celltrion’s four-target candidate

    What it is: Celltrion’s injectable candidate that combines GLP-1, GIP, glucagon and amylin activity in one molecule. It’s the first announced design to add amylin to a retatrutide-style triple agonist.

    Evidence: Preclinical only. Celltrion reports that in obese animals at the same dose it produced greater weight loss than retatrutide, with proportionally less lean mass lost, and that primate data support once-weekly dosing. These are company-reported, non-peer-reviewed results, and no human data exist. An IND is expected in early 2027, per company statements.

    Grade: C. Preclinical and company-reported; too early to judge.

    What this means if you are reading vendor listings

    Three patterns to watch for.

    Names that aren’t names. “GLP-3,” “Triple G,” “Reta-L,” “long-acting GLP” are catalog labels, not molecules. Every compound on this page has a development code and, for most, an INN. A vendor who cannot tell you which one they are selling cannot have tested its identity.

    Half-life claims without pharmacokinetics. A peptide’s half-life comes from its lipid tail or antibody scaffold and is measured in a phase 1 trial. Retatrutide’s is about six days; semaglutide’s about seven; cagrilintide’s about seven to eight; MariTide’s about three weeks. Any claim of a “longer half-life” version of a weekly peptide should come with a published number. If the vendor’s answer is a different fatty acid chain, that is a different molecule with no human data at all.

    Approval that isn’t your approval. Mazdutide and ecnoglutide are approved drugs in China. That is a meaningful review. It is not an FDA review, and it does not change the legal status of research-grade material in the US, where the FDA stated in June 2026 that sales of unapproved GLP-class products to consumers are illegal and Lilly filed six lawsuits in August 2026 against sellers of retatrutide, including research-use-only vendors.

    The field is moving fast enough that half of this page will need updating within six months: CagriSema’s FDA decision is due this quarter, retatrutide’s filing is planned for early 2027, MariTide phase 3 reads out around the same time, and SYNCHRONIZE-CVOT is due before year end. I’ll post grade changes as they land.

    Sources

    • United Laboratories / Novo Nordisk, UBT251 phase 2 topline releases, February 24 and March 25, 2026
    • Innovent Biologics, mazdutide NMPA approvals (June 27 and September 19, 2025); Ji L et al., Once-weekly mazdutide in Chinese adults with obesity or overweight, NEJM 2024, doi:10.1056/NEJMoa2411528
    • Sciwind Biosciences, ecnoglutide NMPA approval announcements, January 30 and March 6, 2026
    • Boehringer Ingelheim, SYNCHRONIZE-1 topline (April 28, 2026) and ADA 2026 presentation; SYNCHRONIZE-1 and SYNCHRONIZE-2 in NEJM, June and October 2026
    • Amgen, MariTide phase 2 (NEJM 2025); ClinicalTrials.gov MARITIME-1 and MARITIME-2 records
    • Eli Lilly, eloralintide phase 2 and EASD 2026 presentation (September 30, 2026)
    • Novo Nordisk, REDEFINE 4 company announcement, February 23, 2026
    • FDA statement on unapproved incretin products, June 2026; Eli Lilly press release on retatrutide lawsuits, August 12, 2026
    • Celltrion. Press release on CT-G32 preclinical development, May 29, 2026 (company-authored). celltrion.com
    • Seoul Economic Daily. “Celltrion to Begin Trials of World’s First Quadruple-Acting Obesity Drug,” Nov 4, 2026. en.sedaily.comLeave a comment

    Peptide Briefs is an independent reference and does not sell anything. Its owners co-own a research-peptide vendor; that is disclosed on every page. Nothing here is medical advice.

  • A sterility recall, a regulatory signal, and two claims that outran their sources

    A sterility recall, a regulatory signal, and two claims that outran their sources

    What I could confirm this week in peptide news, and what I couldn’t.

    Originally posted on Substack

    There was a lot of noise in the peptide feed this week. Here is the short version: what I could confirm from a source, what I couldn’t, and what to watch.

    Subscribe

    1. Two compounded GLP-1 recalls over sterility

    Apothecary Pharma. Apothecary Pharma LLC, a 503B outsourcing facility in Cary, North Carolina, recalled 22 lots of compounded tirzepatide (18 mg/mL, 4 mL multi-dose vials) and one lot of an NAD+ injection. The reason given: the firm “cannot assure the product is sterile.”

    What that does and doesn’t mean:

    • It is voluntary and firm-initiated, and FDA classified it Class II.
    • No illnesses are reported in the coverage I read.
    • “Can’t assure sterility” is a documentation finding. It is not a finding that contamination was detected.
    • FDA issued a warning letter to the firm after a May 2025 inspection that cited insanitary conditions in sterile drug production. The coverage does not say whether the recall is connected to those findings, so I won’t connect them either.

    Carolina Infusion. A widely shared post also described a second recall, by Carolina Infusion, LLC of Ridgeland, South Carolina. FDA’s Enforcement Report lists it. One record I reviewed covers compounded semaglutide 3 mg/mL syringes, Class II, with the reason given as lack of assurance of sterility “related to formulation using bacteriostatic water” and “related to processing equipment used in compounded product.” That wording points at the manufacturing process, not at a contamination finding. The beyond-use dates on the lots in that record have all passed. I only reviewed one record, so I’m not stating how many products or lots the recall covers.

    Takeaway: for any injectable, the paperwork is part of the product. If a manufacturer can’t document the process, that is the story, whether or not anyone got sick.

    1. FDA may be weighing an interim path for “wellness” peptide compounding

    The Capitol Forum reported on October 21 that FDA is seeking an interim pathway that would allow compounding of certain unapproved wellness peptides before final rulemaking. The article is paywalled, so I only have the headline and a short summary. I don’t know the scope, which peptides, or any dates.

    So: a signal, not a decision. Nothing has changed in what is allowed today. If details become public, I’ll cover them properly.

    1. Enforcement is moving past the “research use only” label

    Eli Lilly filed suit in August against six U.S. companies over unauthorized retatrutide, and says it referred information on more than 200 individuals and entities to authorities. It is also asking payment processors, platforms and shippers to stop unauthorized sales. A law-firm summary of the cases notes that FDA treated one seller’s retatrutide as an unapproved new drug in March, despite research-use-only wording, relying on the company’s website and the claims it made.

    The pattern worth noticing is that intended use is judged from conduct, not from the label. Marketing, social posts, and how a seller talks to customers all count. That applies to every seller and every influencer in this space, and it is a good reason to be skeptical of anyone who says “it’s labeled RUO, so anything goes.”

    Retatrutide itself is still investigational. Per the same summary, FDA says it cannot be compounded.

    1. Two claims that outran their sources

    SenoMune-0257. A viral post called it a “cancer curing peptide” that “completed pre-clinical studies successfully.” The only coverage I found is a trade-press article built on a company press release from Immorta Bio. It describes a nine-amino-acid, AI-designed peptide intended to train immune cells to remove senescent cells, framed around diseases of aging. It does not call it a cancer treatment, it gives no data on models or results, and human evaluation is described as anticipated before year-end, not started.

    A MOTS-c kidney study. Another post said MOTS-c “could be the peptide that shields kidneys from diabetes,” citing a mouse and cell-culture paper. I could not find that paper, so I can’t confirm the details. Even if it holds up exactly as described, mice and lab cells point to where to look. They don’t show what happens in people.

    A quick filter for any viral peptide post:

    1. Mice, cells, or humans?
    2. Correlation or intervention?
    3. Is there a DOI? If the poster can’t link it, treat it as a rumor.

    What I’m watching

    • Any FDA detail on an interim wellness-peptide pathway.
    • The retatrutide court case over classification and jurisdiction.
    • A DOI for the MOTS-c kidney paper.

    This is a news summary and not medical, legal or purchasing advice.

    Sources

    • Managed Healthcare Executive, October 21, 2026: Apothecary Pharma recall of compounded tirzepatide and NAD+ vials over sterility concerns (managedhealthcareexecutive.com)
    • FDA Enforcement Report, Carolina Infusion, LLC (accessdata.fda.gov)
    • The Capitol Forum, Health Care Weekly, October 21, 2026 (thecapitolforum.com), paywalled
    • Vedder Price, “Lilly’s Retatrutide Lawsuits Spotlight Expanding Enforcement Risk for the Peptide and GLP-1 Industry” (vedder.com)
    • RuntimeWire, “Immorta Bio completes preclinical studies for AI-designed senolytic peptide” (runtimewire.com)

    Disclosure: I co-own Agape Compounds, a research-use-only peptide company. Peptide Briefs is written independently of it.

  • The Peptide Briefs Top Ten: Week of Oct 19, 2026

    The Peptide Briefs Top Ten: Week of Oct 19, 2026

    What the internet argued about this week, and what each topic really means.

    Every week, ten peptide topics take over the feeds, the news and the comment sections. This is the list, in order, with one line on why each matters.

    How it’s built: news coverage, Reddit and Substack discussion, and public posts on X, ordered by editorial judgment. It is not a measured ranking. I can’t measure X directly, and every claim below is attributed to its source.

    1. FDA’s interim access policy. Sent to the White House on Oct 14. The text isn’t public. Enforcement discretion is not approval, and the evidence grades haven’t moved.
    2. GLP-1 compounds. They account for most online peptide conversation, by a wide margin.
    3. Retatrutide. Lilly’s TRIUMPH-1 topline results are driving interest. The data aren’t yet peer-reviewed, and the drug isn’t approved.
    4. Platforms writing the rules. TikTok is reported to block searches for some peptide names. A screenshot of an Apple letter shows it objecting to reconstitution calculators. Neither is confirmed by the company.
    5. FDA versus “research use only.” August warning letters made the point that a disclaimer doesn’t outweigh the rest of a site’s marketing.
    6. COAs and “verified.” Everyone says the word. Few define it. Does it mean the lab confirmed the report, or the seller uploaded a PDF?
    7. Harm stories versus the access push. Media reports of people hurt by peptides are running alongside the political push for wider access.
    8. Influencer hype and expert warnings. Doctors in several countries are pushing back on social-media promotion.
    9. Access politics and polls. Sponsor-funded polling shows support for pharmacy access. Read it with the sponsor in mind.
    10. Mitochondrial peptides. MOTS-c, SS-31 and Humanin keep coming up, often with a level in the body mistaken for an outcome.

    WHAT MOVED THIS WEEK
    This is the first edition, so there is nothing to compare yet. Next week this section will show what moved up and down.

    YOUR TURN
    Which topic would you move to #1? Reply and tell me.

    Get the Top Ten every Thursday: subscribe on Substack

    I co-own a research-peptide vendor, and Peptide Briefs is editorially independent of it. Nothing here is medical advice.

  • Three of five: what the retatrutide papers say that the press releases didn’t

    TRIUMPH-1 in NEJM, TRIUMPH-2 in The Lancet, same day. The grade stays B. Here’s what moved.

    On September 29, Lilly published two of its retatrutide Phase 3 trials in full on the same day: TRIUMPH-1 in the New England Journal of Medicine and TRIUMPH-2 in The Lancet. With TRANSCEND-T2D-1, published in The Lancet in June, that makes three of the five reported Phase 3 results peer-reviewed. Two remain company topline releases.

    The grade on Peptide Briefs stays B. This post is about why, and about what the papers say that the May and July press releases didn’t.

    Two numbers, both correct

    Lilly’s May headline for TRIUMPH-1 was 28.3% weight loss at 12 mg. The NEJM paper’s primary result is 25.0%. Both appear in Figure 1 of the paper, and the difference is not a correction; it’s two questions. The efficacy estimand asks what happens if every participant stays on drug for 80 weeks. The treatment-regimen estimand, which NEJM reports as primary, counts the people who stopped. Across all three doses the peer-reviewed numbers are 17.6%, 23.7% and 25.0% vs 3.9% on placebo, against topline figures of 19.0%, 25.9% and 28.3%.

    When a vendor or a headline quotes the higher figure, it isn’t wrong. It’s the optimistic one. The same applies to TRIUMPH-2’s 20.8%; the Lancet intention-to-treat number is [insert from paper].

    What TRIUMPH-2 adds

    TRIUMPH-2 is the type 2 diabetes cohort: 1,152 adults, 80 weeks, 4, 9 or 12 mg vs placebo. People with type 2 diabetes reliably lose less on incretin drugs than people without it, and 20.8% at 12 mg is the largest weight loss reported in that population. A1C fell 1.4 to 1.6 points from a 7.7% baseline vs 0.2 on placebo, and up to 40% of participants reached an A1C below 5.7%, the non-diabetic range. Triglycerides fell 39.5%, systolic blood pressure 10.8 mmHg, and hsCRP 58.3% at the top dose.

    What the safety tables add

    Three things the press releases didn’t lead with.

    Dysesthesia. A skin burning or tingling sensation occurred in 12.3% of participants on 9 mg and 12.5% on 12 mg in TRIUMPH-1, against 0.9% on placebo. It isn’t a known GLP-1 or GIP effect; the working assumption is the glucagon component. Lilly reports most cases were mild and resolved on treatment.

    Dropouts by dose don’t line up across trials. In TRIUMPH-1, discontinuation for adverse events rose with dose: 4.1%, 6.5%, 11.2% vs 4.6% placebo. In TRIUMPH-2 the middle dose had the most: 3.8%, 11.6%, 7.7% vs 4.9%. Two trials, two patterns; the honest reading is that we don’t yet know the dose-tolerability curve.

    Orthostatic hypotension. 8.8% at 12 mg vs 0.9% placebo in TRIUMPH-1. Small in absolute terms, ten-fold relative.

    Heart rate, the question most readers have asked, isn’t in the main NEJM tables. It’s in the supplementary appendix, and the page will be updated when we’ve read it rather than summarized from a summary.

    Why B, not A

    A on our scale means the full Phase 3 program is peer-reviewed and a regulator has reviewed the safety file. Three of five is not the program. Lilly says the BLA goes to FDA in Q1 2027; nothing has been reviewed yet. TRIUMPH-5, the head-to-head against tirzepatide, and the 10,000-participant outcomes trial are still running.

    B is not a hedge. It’s the largest weight-loss effect ever recorded in a drug trial, replicated three times in peer-reviewed form, with a safety profile that’s heavier than tirzepatide’s at the top doses and one new adverse event that needs explaining. That’s what B means.

  • The Retatrutide Court Case: What’s Actually at Stake

    Troy Snyder, Sept 2026

    If you’ve been tracking Retatrutide’s evidence record with us — the TRIUMPH trials, the June Lancet publication, the EASD data landing September 30 — there’s a separate story developing this week that has nothing to do with clinical data and everything to do with whether any of it matters in the way you’d expect.

    On September 21, the DOJ filed a letter in Eli Lilly v. FDA (7th Circuit, No. 26-1301), a case that’s been quietly working through the courts and is about to get a lot louder. Oral arguments are Thursday, September 24, 9:30am, Chicago.

    What the case is actually about

    Strip away the legal language and it comes down to one question: is Retatrutide a peptide drug, or is it a protein/biologic?

    That sounds like a technicality. It isn’t. The two classifications sit inside completely different regulatory frameworks, and which one Reta lands in determines the entire competitive landscape around it going forward.

    • Lilly’s position: Retatrutide should be classified as a protein/biologic.
    • FDA’s position: It’s a peptide drug and doesn’t meet the agency’s own definition of a protein.

    The DOJ’s letter this week is procedural but consequential — it’s pointing the appeals court toward a recent Seventh Circuit precedent (Franco v. Chobani, 2026) holding that when an agency’s interpretation of its own scientific definitions is at issue, that interpretation can still carry significant weight with courts, even post-Chevron. In plain terms: DOJ is telling the judges not to second-guess FDA’s classification lightly.

    Why the classification actually matters

    If Reta gets classified as a biologic:

    • Follow-on/generic-equivalent products go through the biosimilar pathway instead of the standard generic route — a slower, more expensive approval process historically reserved for large, complex molecules.
    • 503A/503B compounding pharmacies lose their normal drug-compounding exemptions for biologics, which changes who can legally produce Reta-adjacent formulations and under what rules.

    If Reta stays classified as a peptide drug:

    • It remains inside the traditional drug framework, where standard generic pathways apply.
    • 503A/503B compounding exemptions can still apply, provided other regulatory requirements are met.

    Neither outcome is good or bad in the abstract but they’re genuinely different worlds for anyone tracking availability, pricing, and the broader compounding/RUO ecosystem that sits adjacent to this compound’s supply chain.

    What this means for the grey market

    The 503A/503B compounding question isn’t just a pharmacy-industry detail, it’s the actual bridge between this court case and the broader research-peptide ecosystem, RUO sourcing included.

    If Reta moves into the biosimilar framework, compounding pharmacies lose the exemptions that currently let them produce Reta-adjacent formulations more freely. That tends to push demand in one of two directions, and it’s genuinely unclear which wins out:

    • Tighter compounding rules could push more demand toward RUO/research-only channels as the compounding pathway narrows, the same pattern seen with other GLP-1 compounds when compounding pharmacies faced restrictions.
    • Or it could do the opposite: a high-profile classification fight tends to put the entire peptide category under a brighter regulatory spotlight, RUO sourcing included, not just the specific compound in litigation. Increased scrutiny on one part of the ecosystem has historically spilled over into stricter enforcement, platform bans, and payment-processor caution across the board — something we’ve experienced directly this month.

    We’re not going to speculate on which direction wins, because neither outcome is something we’d base a customer-facing claim on before it actually happens. What we can say plainly: this case is worth watching regardless of whether you buy compounded, RUO, or anything else in this space. The ruling reshapes incentives for the whole supply chain, not just Lilly’s own product line.

    What we’re watching for

    We’ll be straight about where we sit on this: we don’t have a legal opinion on how the classification question should be decided, that’s genuinely a matter for the courts to work out, and we’re not lawyers. But we do have a rooting interest, and we’re not going to pretend otherwise. If Reta stays classified as a peptide drug, the compounding and RUO ecosystem this whole site operates in keeps more room to breathe. If Lilly wins, that room narrows. That’s not a legal argument for either side, it’s just an honest disclosure of where our interest lies, same as we disclose our ownership stake in Agape on multiple pages of this site.

    Oral arguments are Thursday. A ruling likely won’t land immediately; appellate decisions in cases like this often take weeks to months after arguments, but the reasoning that comes out of Thursday’s session will be the first real signal of which way this is heading.

    We’ll cover the outcome in Grade Changes once there’s something concrete to report. For now, this is a “know it’s coming” post, not a “here’s the answer” post — and we’d rather tell you that plainly than manufacture certainty we don’t have.

    — Troy

    Peptide Briefs is an independent research library. This piece covers regulatory proceedings, not clinical evidence — Retatrutide’s evidence grade (B) is unaffected by this case and is tracked separately.